Milkardil 250 mg No. 40

Author Ольга Кияница


Amount in a package 40
Product form Capsules
Manufacturer Nizhpharm (Russia, Nizhny Novgorod)
Registration certificate UA/11740/01/01
The main medicament Milcardil
morion code 172560


active ingredient: meltedion dihydrate (trimethylhydrazine propionate dihydrate);

1 capsule contains meltedion dihydrate (trimethylhydrazine dihydrate propionate), converted to dihydrate without adsorbed moisture - 250 mg;

Excipients: potato starch, silicon dioxide, colloidal anhydrous, calcium stearate.

Capsule: titanium dioxide E 171, gelatin.

Medicinal form


Pharmacotherapeutic group. Means that affect the cardiovascular system. Other cardiological preparations. PBX code С01Е В17.


  • In the complex therapy of coronary heart disease (angina pectoris, chronic heart failure, dyshormonal cardiomyopathy);
  • acute circulatory disorders in the retina of the eye, cerebrovascular accident (stroke, cerebrovascular insufficiency);
  • withdrawal syndrome in chronic alcoholism (in combination with specific alcoholism therapy);
  • reduction of work capacity, physical overload, including athletes.


Hypersensitivity to the components of the drug, increased intracranial pressure (with a violation of venous outflow, intracranial tumors). Children's age.

Method of administration and dose

Assign adults internally.

Cardiovascular disease or cerebrovascular accident.

As part of complex therapy for 0,5-1,0 g per day in one treatment (or divide the daily dose by 2 receptions). Course of treatment - 4-6 weeks.

Cardialgia on the background of dyshormonal dystrophy of the myocardium - internally at 0.5 g per day in one treatment (or divide the daily dose by 2 doses). Course of treatment - 12 days.

Acute phase of cerebrovascular accident - use the injection form of the drug for 10 days, then go on to use the drug internally for 0.5-1.0 g per day in one treatment (or divide the daily dose by 2 doses). Course of treatment - 4-6 weeks.

Chronic disorders of the cerebral circulation - internally, 0.5 g per day in one treatment (or divide the daily dose by 2 doses). Course of treatment - 4-6 weeks.

Repeated courses (usually 2-3 times a year) are possible after consultation with the doctor.

Intellectual and physical overload, including athletes .

Apply 0.25 g 4 times a day. The course of treatment is 10-14 days. If necessary, the treatment is repeated in 2-3 weeks.

Athletes are assigned 0,5-1,0 g internally 2 times a day, before training. Duration of the course in the preparatory period - 14-21 days, during the competition - 10-14 days.

Chronic alcoholism.

For 0.5 g 4 times a day. Course of treatment - 7-10 days.

The maximum daily dose is 1 g.

Adverse reactions

Rarely - allergic reactions (redness, rash, itching, swelling), dyspeptic phenomena, tachycardia, excitement, changes in blood pressure.


Possible excitation, lowering blood pressure, nausea, vomiting. Treatment: gastric lavage, cleansing enema, symptomatic remedies.

Application during pregnancy and lactation

Safe use during pregnancy has not been proven. To avoid possible adverse effects on the fetus during pregnancy, the drug is not prescribed. It was not clear whether the drug was released into mother's milk. If necessary, during lactation, breastfeeding is discontinued.


Not applicable.

Application features

Due to the possibility of developing an exciting effect, the drug is used in the first half of the day. Mildardil is not a first line drug in the treatment of acute coronary syndrome.

It is used with caution in diseases of the liver and / or kidneys, especially for a long time.

Ability to influence the reaction speed when driving or working with other mechanisms

Patients should be warned about the need to take caution when dealing with potentially dangerous mechanisms and driving, as the potential for the development of an excitatory effect is possible.

Interaction with other drugs and other types of interactions.

Strengthens the action of coronary substances, some antihypertensives, cardiac glycosides. Possible combination with antianginal drugs, anticoagulants, antiarrhythmic drugs, diuretics, bronchodilators. In view of the possible development of moderate tachycardia and arterial hypotension, caution should be exercised when combined with nitroglycerin, nifedipine, alpha-blockers, hypotensive agents and peripheral vasodilators.

Pharmacological properties

Pharmacodynamics. The synthetic analogue of gamma-butyrobatein inhibits gamma-butyrobate dihydroxinaz, reduces the synthesis of carnitine and the transport of long-chain fatty acids through cell shells, prevents the accumulation of activated forms of unreacted fatty acids in the cells - derivatives of acylarnitine and acylcoenzymes A.

Cardioprotective agent, normalizes the metabolism of the myocardium. In conditions of ischemia restores the balance of the processes of oxygen delivery and its consumption in cells, prevents the transport of ATP; At the same time, it activates glycolysis, which proceeds without additional oxygen consumption. As a result of lowering the concentration of carnitine, gamma-butyrobatein, which has vasodilating properties, is highly synthesized. The mechanism of action determines the variety of its pharmacological effects: increased efficiency, reduced symptoms of mental and physical strain, activation of tissue and humoral immunity, cardioprotective effect. In the case of acute ischemic injury, the myocardium slows the appearance of necrotic area, accelerates the rehabilitation period. With heart failure increases the contractility of the myocardium, increases the tolerance to physical activity, reduces the frequency of angina attacks.In acute and chronic ischemic violations of the cerebral circulation, blood circulation improves in the cell of ischemia, contributing to redistribution of blood in favor of an ischaemia site. Effective in the case of vascular and dystrophic pathology of the bottom of the eye. Typical is the tonic effect on the central nervous system, elimination of functional disorders of the somatic and autonomic nervous system in patients with chronic alcoholism in abstinence syndrome.

Pharmacokinetics. After oral administration is rapidly absorbed, bioavailability - 78%. The maximum concentration in blood plasma is reached 1-2 hours after intravenous administration. Metabolizes in the body with the formation of two major metabolites that are excreted by the kidneys. The half-life at ingestion depends on the dose internally, it is 3-6 hours.

Basic physical and chemical properties

hard gelatin capsules number 1 in white color. The contents of the capsule are white to almost white crystalline powder, a weak specific odor is allowed. Powder is hygroscopic, clumping is allowed.

Expiration date

3 years.

Storage conditions

Keep in a dry, inaccessible place for children at a temperature not higher

25º C.


250 mg capsules. On 10 capsules in a blister of polyvinylchloride film and aluminum foil, 4 blisters in a cardboard bundle.

Category of departure

By prescription.

0.00 avg. rating (0% score) - 0 votes - votes